{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:43:19Z","timestamp":1777131799505,"version":"3.51.4"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Metabolic syndrome is a complex and heterogeneous pathology characterized by a cluster of biochemical, clinical, and metabolic factors that came together in raising the risk of cardiovascular diseases, type 2 diabetes mellitus, and all-cause mortality. Some of these features are well defined in this syndrome like: obesity, inflammation, hypertension, insulin resistance, atherosclerotic dyslipidemias, endothelial dysfunction, and inflammation. This circuit is intermediated by a complex network of hormones, cytokines, transcription factors, and adipokines, among others. Some like leptin, adiponectin, Plasminogen activator inhibitor-1, interleukin-6, Tumor necrosis factor, and their influence on the metabolic syndrome are well described in the literature and new players are described continuously. One novel player was described in 2016 by Romere et al as a fasting-induced glycogenic protein hormone named asprosin.<\/jats:p>\n            <jats:p>In order to perform a state-of-the-art, nonsystematic review of asprosin, a study of the available literature was carried out in the main database (Pubmed) and the results were studied and correlated to better understand the mechanism of action of this hormone.<\/jats:p>\n            <jats:p>Asprosin is not only associated with the metabolic syndrome features like glucose and lipid metabolism, insulin resistance, obesity and inflammation but also in other pathologies metabolic syndrome related like diabetic retinopathy, polycystic ovary syndrome and anorexia nervosa. A limited number of pathways were already unveiled although much more research is needed to better understand the therapeutical potential of asprosin in the metabolic syndrome.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/j.pbj.0000000000000108","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T21:41:05Z","timestamp":1607636465000},"page":"e108","source":"Crossref","is-referenced-by-count":24,"title":["A state of the art review on the novel mediator asprosin in the metabolic syndrome"],"prefix":"10.1097","volume":"5","author":[{"given":"Carla","family":"Lu\u00eds","sequence":"first","affiliation":[{"name":"Biochemistry Unit, Department of Biomedicine, Faculty of Medicine, University of Porto"},{"name":"i3S - Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto"}]},{"given":"R\u00faben","family":"Fernandes","sequence":"additional","affiliation":[{"name":"i3S - Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto"},{"name":"School of Health, Polytechnic of Porto (ESS\/P.PORTO)"}]},{"given":"Raquel","family":"Soares","sequence":"additional","affiliation":[{"name":"Biochemistry Unit, Department of Biomedicine, Faculty of Medicine, University of Porto"},{"name":"i3S - Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto"}]},{"given":"Pedro","family":"von Hafe","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, University of Porto"},{"name":"S\u00e3o Jo\u00e3o Hospitalar Center, Porto, Portugal."}]}],"member":"276","published-online":{"date-parts":[[2020,11]]},"reference":[{"key":"R1-20231106","first-page":"105","article-title":"Studien ueber das Hypertonie-Hyperglyca \u201cmie- Hyperurika\u201d miesyndrom","volume":"1","author":"E","year":"1923","journal-title":"Zentralblatt fuer Inn Medizin."},{"key":"R2-20231106","first-page":"452","article-title":"Abdominal obesity as important component of insulin-resistance syndrome","volume":"9","author":"Despres","year":"1993","journal-title":"Nutrition."},{"key":"R3-20231106","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2337\/diab.37.12.1595","article-title":"Role of insulin resistance in human disease","volume":"37","author":"Reaven","year":"1988","journal-title":"Diabetes."},{"key":"R4-20231106","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1001\/archinte.1989.00390070054005","article-title":"The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension","volume":"149","author":"Kaplan","year":"1989","journal-title":"Arch Intern Med."},{"key":"R5-20231106","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1210\/er.2008-0024","article-title":"The metabolic syndrome","volume":"29","author":"Cornier","year":"2008","journal-title":"Endocr Rev."},{"key":"R6-20231106","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","article-title":"The metabolic syndrome","volume":"365","author":"Eckel","year":"2005","journal-title":"Lancet."},{"key":"R7-20231106","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1079\/BJN20041213","article-title":"Adipokines: inflammation and the pleiotropic role of white adipose tissue","volume":"92","author":"Trayhurn","year":"2004","journal-title":"Br J Nutr."},{"key":"R8-20231106","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.coph.2004.03.003","article-title":"The delicate balance between fat and muscle: Adipokines in metabolic disease and musculoskeletal inflammation","volume":"4","author":"Nawrocki","year":"2004","journal-title":"Curr Opin Pharmacol."},{"key":"R9-20231106","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.cell.2016.02.063","article-title":"Asprosin, a fasting-induced glucogenic protein hormone","volume":"165","author":"Romere","year":"2016","journal-title":"Cell."},{"key":"R10-20231106","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.cmet.2019.05.022","article-title":"OLFR734 Mediates Glucose Metabolism as a Receptor of Asprosin","volume":"30","author":"Li","year":"2019","journal-title":"Cell Metab."},{"key":"R11-20231106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2018\/6313484","article-title":"Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion","volume":"2018","author":"Wang","year":"2018","journal-title":"Mediators Inflamm."},{"key":"R12-20231106","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/jdi.13148","article-title":"Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus","volume":"11","author":"Zhang","year":"2020","journal-title":"J Diabetes Investig."},{"key":"R13-20231106","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.cca.2017.10.034","article-title":"Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride","volume":"489","author":"Zhang","year":"2019","journal-title":"Clin Chim Acta."},{"key":"R14-20231106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cophys.2019.04.007","article-title":"The role of gut hormones in the pathogenesis and management of obesity","volume":"12","author":"Makaronidis","year":"2019","journal-title":"Current Opinion in Physiology."},{"key":"R15-20231106","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/nm.4432","article-title":"Asprosin is a centrally acting orexigenic hormone","volume":"23","author":"Duerrschmid","year":"2017","journal-title":"Nat Med."},{"key":"R16-20231106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2020.00064","article-title":"Asprosin: a novel player in metabolic diseases","volume":"11","author":"Yuan","year":"2020","journal-title":"Front Endocrinol."},{"key":"R17-20231106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/2521096","article-title":"Saliva and blood asprosin hormone concentration associated with obesity","volume":"2019","author":"Ugur","year":"2019","journal-title":"Int J Endocrinol."},{"key":"R18-20231106","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/s41366-018-0248-1","article-title":"Serum asprosin levels and bariatric surgery outcomes in obese adults","volume":"43","author":"Wang","year":"2019","journal-title":"Int J Obes."},{"key":"R19-20231106","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000503808","article-title":"Serum asprosin concentrations are increased and associated with insulin resistance in children with obesity","volume":"75","author":"Wang","year":"2020","journal-title":"Ann Nutr Metab."},{"key":"R20-20231106","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/ped.14176","article-title":"Increased serum circulating asprosin levels in children with obesity","volume":"62","author":"S\u00fcnnet\u00e7i Silistre","year":"2020","journal-title":"Pediatr Int."},{"key":"R21-20231106","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1159\/000500523","article-title":"Decreased circulating levels of asprosin in obese children","volume":"91","author":"Long","year":"2019","journal-title":"Horm Res Paediatr."},{"key":"R22-20231106","article-title":"Increased plasma asprosin levels in patients with drug-naive anorexia nervosa","author":"Hu","year":"2020","journal-title":"Eat Weight Disord."},{"key":"R23-20231106","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.mce.2019.03.001","article-title":"Asprosin impairs insulin secretion in response to glucose and viability through TLR4\/JNK-mediated inflammation","volume":"486","author":"Lee","year":"2019","journal-title":"Mol Cell Endocrinol."},{"key":"R24-20231106","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.cell.2010.02.034","article-title":"Endoplasmic reticulum stress and the inflammatory basis of metabolic disease","volume":"140","author":"Hotamisligil","year":"2010","journal-title":"Cell."},{"key":"R25-20231106","doi-asserted-by":"crossref","first-page":"20888","DOI":"10.1002\/jcp.28694","article-title":"Asprosin attenuates insulin signaling pathway through PKC(-activated ER stress and inflammation in skeletal muscle","volume":"234","author":"Jung","year":"2019","journal-title":"J Cell Physiol."},{"key":"R26-20231106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm8050666","article-title":"Aerobic exercise training decreases hepatic asprosin in diabetic rats","volume":"8","author":"Ko","year":"2019","journal-title":"J Clin Med."},{"key":"R27-20231106","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.placenta.2020.02.004","article-title":"Continuous elevation of plasma asprosin in pregnant women complicated with gestational diabetes mellitus: a nested case-control study","volume":"93","author":"Zhong","year":"2020","journal-title":"Placenta."},{"key":"R28-20231106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.peptides.2019.170132","article-title":"Asprosin in umbilical cord of newborns and maternal blood of gestational diabetes, preeclampsia, severe preeclampsia, intrauterine growth retardation and macrosemic fetus","volume":"120","author":"Baykus","year":"2019","journal-title":"Peptides."},{"key":"R29-20231106","doi-asserted-by":"crossref","DOI":"10.1097\/IAE.0000000000002776","article-title":"Altered blood and aqueous humor levels of asprosin, 4-hydroxynonenal, and 8-hydroxy-deoxyguanosine in patients with diabetes mellitus and cataract with and without diabetic retinopathy","author":"Oruc","year":"2020","journal-title":"Retina."},{"key":"R30-20231106","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.510290235","article-title":"Association of diabetes mellitus and chronic hepatitis C virus infection","volume":"29","author":"Mason","year":"1999","journal-title":"Hepatology."},{"key":"R31-20231106","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/10520295.2020.1714732","article-title":"Are adropin, apelin, elabela, asprosin and betatrophin biomarkers for chronic hepatitis and staging of fibrosis?","volume":"95","author":"Eser Karlidag","year":"2020","journal-title":"Biotech Histochem."},{"key":"R32-20231106","first-page":"827","article-title":"Study of the role and mechanism of asprosin\/spartin pathway in cardiac microvascular endothelial injury induced by diabete mellitus","volume":"50","author":"Chen","year":"2019","journal-title":"Sichuan da xue xue bao Yi xue ban=J Sichuan Univ Med Sci Ed."},{"key":"R33-20231106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lfs.2019.03.010","article-title":"Asprosin improves the survival of mesenchymal stromal cells in myocardial infarction by inhibiting apoptosis via the activated ERK1\/2-SOD2 pathway","volume":"231","author":"Zhang","year":"2019","journal-title":"Life Sci."},{"key":"R34-20231106","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.ajem.2017.12.032","article-title":"A novel biochemical marker for predicting the severity of ACS with unstable angina pectoris: asprosin","volume":"36","author":"Acara","year":"2018","journal-title":"Am J Emerg Med."},{"key":"R35-20231106","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/09513590.2018.1512967","article-title":"Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome","volume":"35","author":"Alan","year":"2019","journal-title":"Gynecol Endocrinol."},{"key":"R36-20231106","first-page":"1","article-title":"Plasma asprosin levels are associated with glucose metabolism, lipid, and sex hormone profiles in females with metabolic-related diseases","volume":"9","author":"Li","year":"2018","journal-title":"Mediators Inflamm."},{"key":"R37-20231106","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2337\/dbi19-0009","article-title":"Energy regulation mechanism and therapeutic potential of asprosin","volume":"69","author":"Hoffmann","year":"2020","journal-title":"Diabetes."},{"key":"R38-20231106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2018.00156","article-title":"Peripheral CB1 receptor neutral antagonist, AM6545, ameliorates hypometabolic obesity and improves adipokine secretion in monosodium glutamate induced obese mice","volume":"9","author":"Ma","year":"2018","journal-title":"Front Pharmacol."}],"container-title":["Porto Biomedical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/j.pbj.0000000000000108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T10:01:43Z","timestamp":1699264903000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/j.pbj.0000000000000108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/j.pbj.0000000000000108","relation":{},"ISSN":["2444-8664"],"issn-type":[{"value":"2444-8664","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}